Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non‐alcoholic fatty liver disease by up‐regulating the FGF21/PGC‐1α pathway

BACKGROUND AND PURPOSE: Non‐alcoholic fatty liver disease (NAFLD) is considered to be one of the most common chronic liver diseases across worldwide. Astaxanthin (Ax) is a carotenoid, and beneficial effects of astaxanthin, including anti‐oxidative, anti‐inflammatory, and anti‐tumour activity, have b...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Pharmacol
Autors principals: Wu, Liwei, Mo, Wenhui, Feng, Jiao, Li, Jingjing, Yu, Qiang, Li, Sainan, Zhang, Jie, Chen, Kan, Ji, Jie, Dai, Weiqi, Wu, Jianye, Xu, Xuanfu, Mao, Yuqing, Guo, Chuanyong
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7393201/
https://ncbi.nlm.nih.gov/pubmed/32446270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15099
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars